Final Efficacy and Safety Results from the 1703 Phase Ib/II Study of Elotuzumab/Lenalidomide/Dexamethasone in Relapsed/Refractory MM


Final Efficacy and Safety Results from the 1703 Phase Ib/II Study of Elotuzumab/Lenalidomide/Dexamethasone in Relapsed/Refractory MM
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Ola Landgren, MD, PhD (2/9/15)
Richardson PG et al. Final results for the 1703 phase 1b/2 study of elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Proc ASH 2014;Abstract 302.

Dr Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York.